Dow Down0.32% Nasdaq Down0.62%

Array BioPharma Inc. (ARRY)

3.19 Down 0.02(0.62%) Apr 29, 4:00PM EDT
|After Hours : 3.19 0.00 (0.00%) Apr 29, 4:55PM EDT
ProfileGet Profile for:
Array BioPharma Inc.
3200 Walnut Street
Boulder, CO 80301
United States - Map
Phone: 303-381-6600

Index Membership:N/A
Full Time Employees:156

Business Summary 

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s drugs in Phase III clinical trials include Binimetinib and Encorafenib for the treatment of cancer. Its drug candidates in Phase II clinical trials include Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASC08/Danoprevir, a protease inhibitor for Hepatitis C virus; ASLAN001/ARRY-543, a pan-HER inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; and LY2606368, a chk-1 inhibitor for cancer. The company’s Phase Ib drug candidate comprises GDC-0575, a chk-1 inhibitor for cancer; and ONT-380/ARRY-380, a HER2 inhibitor for breast cancer, as well as Phase I drug candidate includes GDC-0994, an ERK inhibitor for cancer and LOXO-101, a PanTrk inhibitor for cancer. Array BioPharma Inc. has collaboration agreements with Biogen Idec MA Inc.; Array and Celgene Corporation and Celgene Alpine Investment Co., LLC; Genentech, Inc.; Loxo Oncology, Inc.; Novartis International Pharmaceutical Ltd.; and Oncothyreon Inc, as well as a collaboration with Dana-Farber Cancer Institute. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Array BioPharma Inc.

Corporate Governance 
Array BioPharma Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 9. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 8; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Ron Squarer BSc (Biochemistry), MBA, 49
Chief Exec. Officer and Director
Mr. David Jay Horin CPA, 48
Interim Chief Financial Officer
Mr. Andrew Robbins , 40
Chief Operating Officer
Mr. John R. Moore , 52
VP, Gen. Counsel and Sec.
Dr. Victor Sandor M.D., C.M, 50
Chief Medical Officer
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders